Patients appear to be at higher risk of heart problems or stroke when prescriptions for the newest cholesterol-lowering drugs are rejected by insurance companies or unfilled by patients, according to new research in Circulation: Cardiovascular Quality and Outcomes, an American Heart Association journal. The drugs, PCSK9 inhibitors (PCSK9i), can substantially lower levels of low-density lipoprotein… Continue reading Rejected and Unfilled Prescriptions for New, Pricier Cholesterol Drugs Tied to Higher Heart, Stroke Risk
Tag: PCSK9 inhibitors
Insurance Approval Lagging on Costly New Cholesterol Drug
Less than half of patients received their insurer’s approval for prescriptions of the type of cholesterol-lowering drug known as PCSK9 inhibitors, according to new research in the American Heart Association’s (AHA) journal Circulation. PCSK9 inhibitors, like Repatha (evolocumab) and Praluent (alirocumab), work by increasing the removal of low-density lipoprotein (LDL) or “bad” cholesterol from the… Continue reading Insurance Approval Lagging on Costly New Cholesterol Drug